STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

MGF (Mechano Growth Factor)

Also known as

Mechano Growth Factor · Mechano-Growth Factor · IGF-1 Ec · IGF-1Ec · IGF-IEc · IGF-1 Eb (rodent nomenclature confusion) · MGF-E · MGF E-peptide · MGF-Ct24E · MGF-24aa-E · non-PEGylated MGF · native MGF · unmodified MGF · IGF-1Ec E-domain peptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Local IM / SubQ Growth factors

Local — people pin it in or near just-trained muscle.

What people say MGF can mean endogenous IGF-1Ec splice biology or a synthetic short E-domain peptide sold as a research product. Those are not interchangeable identities, and primary cell studies of the synthetic peptide conflict. Doses people talk about
Inspected bilateral report200 mcg reported bilaterally

The commenter did not answer whether 200 mcg meant session total or each biceps, so the ambiguity is retained.

Broader per-injection talk~100–300 mcg

Repeated across legacy bodybuilding and peptide-protocol summaries; not independently verified as a standardized product or clinical dose.

Upper community talk~300–400 mcg per session

Sometimes described as split across trained sites; this remains community chart language with more site-volume and nonspecific-side discussion.

These are descriptive community amounts, not a progression. Exact construct and content were unverified, and no checked human dose-finding trial established a hypertrophy regimen.

Half-life & effect duration

Half-life in the body
  • Common community estimateAbout 5–7 minutes
  • Other community estimatesAbout 2–5 minutes; wider summaries give 2–15 minutes
Felt duration people report
  • Positive reportsFaster healing or subtle fullness and recovery
  • Other accountsNo benefit
Timing context & sources
How it may feel There is usually no stimulant-like acute effect. Public accounts range from painful injection or no change to possible local healing or fullness, and the positive stories are often confounded by injury recovery, training or other compounds.
Cycles people discuss Community use is commonly organized around roughly 4–6 week training blocks or shorter tests, with training-day pulses. These are bodybuilding conventions, not human dose-finding or long-term safety evidence. Timing Native MGF community schedules are tied to the trained muscle and placed immediately after resistance training, often within 30–60 minutes; rest days are usually skipped. This is gym practice, not a validated human timing window. Stacks LR3, DES, HGH, secretagogues and injury-peptide stacks dominate many MGF discussions. These combinations increase glucose, growth-pathway and attribution uncertainty; an outcome cannot be assigned to MGF from a stack report. Watch for Source quality: Contamination, underdosing, wrong peptide, native vs PEG mislabel, C-terminal amidated or other black-market analogs (Esposito et al. 2012 class analytical findings on illicit products) — structural gray-market risk independent of mechanism.
Related
PEG-MGFPEG-IGF-1MK-677

Tap a line for the full notes and source context.

Timing context & sources

Half-life in the body

A human parent-plasma half-life is not established for the exact synthetic MGF product in the reviewed source set.

Community and secondary summaries repeat roughly 2–7 minute estimates, but formal sources reviewed here address identity and in-vitro effects rather than construct-specific human elimination.

This bounded review cannot prove no human PK study exists. Endogenous transcript timing, different stabilized analogs and PEGylated products cannot supply the missing value.

Felt duration people report

The inspected accounts do not establish a repeatable felt-onset or recovery-duration window.

One commenter reported faster healing after 200 mcg worded bilaterally, while others in MGF and PEG-MGF discussions described no benefit or only subtle fullness and recovery.

Anonymous self-reports, unverified product identities, unresolved component mass and injury, training, diet and stack confounding prevent causal timing inference.

  • Reddit r/BodyHackGuide — Experience with PEG-MGF (opens in a new tab)Discussion includes a non-PEG MGF reply worded as 200 mcg bilaterally in each biceps with faster-healing attribution, alongside no-benefit, painful-injection and mostly-fruitless views across MGF products.Anonymous mixed thread, unresolved total-versus-per-side wording, unverified products and strong injury/stack/training confounding.
  • EliteFitness — IGF / PEG-MGF discussion (opens in a new tab)Thread participants discuss mixed outcomes and whether adding PEG-MGF changed results versus IGF alone; the concrete 50 mcg every-other-day amount belongs to IGF, not MGF.Old anonymous forum thread with overlapping IGF and PEG-MGF use; it cannot isolate MGF efficacy, dose or duration and the IGF amount must not be reassigned.

What people say 12

  • Local recovery reports are mixed: One non-PEG MGF commenter described faster biceps healing, while other MGF/PEG-MGF users described no clear benefit or mostly fruitless experimentation. Sleep, food, training, injury course and stacks remain strong confounders. forum
  • Site-focused repair talk: “Pin where you trained” lore for regional recovery/fullness; short half-life is the justification for local IM rather than systemic depot. forum
  • Size / fullness talk: Gradual fullness or measurements over multi-week progressive-overload blocks; single-agent credit is unreliable. forum
  • Satellite-cell / hyperplasia lore: Classic board story — MGF expands the progenitor pool; IGF-1 LR3 (or training/GH) “builds them out.” Pathway storytelling more than fiber-count proof in humans. forum
  • Timing preference claims: Benefit claimed strongest when dosed soon after resistance work into trained heads (within ~30–60 min in many guides). anecdote
  • Vs PEG-MGF practicality trade: Native framed as more “physiological / local / acute”; PEG framed as fewer pins and multi-day coverage with more systemic spillover. Some veterans still prefer native for site work; many switch to PEG for convenience. forum
  • Injury downtime / strain talk: Occasional easier return-to-training narratives; mixed with PT, rest, BPC/TB, and time — causality muddy. forum
  • Stack halo problem: Many “MGF worked” logs also run IGF-1 LR3/DES, HGH/secretagogues, surplus calories, or AAS — attribution is unreliable. forum
  • Expectation reset: Forums repeatedly stress MGF is not steroid-level growth; non-responders and “subtle at best” logs are common when training/calories are already solid. forum
  • Aging / sarcopenia research hook: Endogenous MGF response to loading is described as blunted with age in human biopsy and animal work; this fuels interest but does not establish that injectable research MGF reverses sarcopenia in people. trial
  • Cell data (positive class): MGF-E peptide reported to increase proliferative lifespan and delay senescence of human satellite cells from neonatal/young-adult donors in culture (Kandalla et al. 2011 class findings often cited). lab
  • Animal / loading backdrop: Stretch, injury, and resistance models raise local IGF-1Ec / MGF expression; cardiac and other tissue repair papers exist in animals — backdrop, not gym outcome proof. animal

Doses people talk about 17

  • Broad per-injection band: ~100–300 mcg is the most repeated single-session range for non-PEGylated MGF across bodybuilding and peptide-protocol write-ups. forum
  • Inspected 200 mcg report and broader modal talk: One user described 200 mcg bilaterally in the biceps but did not resolve total versus per-side mass. Broader experienced-user summaries also repeat ~200 mcg post-workout into trained muscle. forum
  • Lower / start band: ~100–150 mcg per session (sometimes ~100 mcg per side bilaterally) appears as beginner or conservative site-work starts. forum
  • Upper community band: ~300–400 mcg per session, sometimes split across multiple trained heads — more site volume and nonspecific side talk; still not clinical doses. forum
  • Vendor titration charts (example style): Starting ~200 mcg → ramp ~400 mcg → “maintenance” ~600 mcg after workout (illustrative clinic/vendor tables; not trial arms). forum
  • Research-summary / wiki-style band: ~100–200 mcg per injection, with notes that short half-life may push more frequent dosing than PEGylated charts. forum
  • Frequency — training-aligned (dominant gym lore): Post-resistance-training only, roughly ~3–5× per week matching hard sessions — not necessarily every calendar day. forum
  • Not daily for convenience like PEG: Classic PEG charts are 2–3×/week multi-day coverage; native charts stay tied to workout timing more often. forum
  • Bilateral / multi-site split: Session total mcg often divided across left/right trained muscles or multiple heads (e.g., 100 mcg/side × 2 = 200 mcg session; advanced logs micro-inject across many points). forum
  • Example session structure (forum style): ~200 mcg total post-WO, split bilaterally into the muscle just trained. forum
  • Timing window: Immediately post-workout preferred; many guides say within ~30–60 minutes. Pre-workout native MGF is less common than post. forum
  • Rest days: Usually skipped for native MGF in bodybuilding lore (save for trained-muscle days); PEG users more often still dose recovery days. forum
  • Titration rule of thumb in guides: Hold a working dose across several training sessions with acceptable site tolerance before increasing; do not double a missed post-workout dose. forum
  • Source uncertainty: Labeled mcg ≠ verified content; native vs PEG mix-ups and D-analog vs L-peptide variance confound log comparisons. forum
  • Suggested chart band (same vendor style): ~200–600 mcg total post-workout depending on titration step — higher than classic forum 100–300 mcg band; treat as chart variance. forum
  • Frequency — short-half-life minority notes: Some protocol comparisons say native MGF “requires more frequent dosing” (even multi-times-daily research framing) because of minutes-scale clearance — this conflicts with the more common training-day-only bodybuilding pattern. forum
  • Framing: Community, vendor-chart, and research-chem protocol ranges only — not medical advice, not prescriptions, not validated athletic doses. No peer-reviewed human dose-finding trial establishes a native MGF hypertrophy protocol. forum

How it may feel 8

  • Day of injection: Usually no stimulant-like buzz; awareness is injection logistics, mild site sting/fullness, and whether IM into a pumped muscle felt rough. forum
  • Days 1–7: Little dramatic cosmetic change; focus on technique, multi-site splits, post-workout window discipline, and whether sleep already explains any soreness shift. forum
  • Weeks 1–2: Easier next-session readiness in targeted muscles is the earliest commonly claimed signal — still confounded. Size claims usually not expected yet. forum
  • Weeks 3–4: Common reassess point on a 4–6 week block; physique or recovery anecdotes that land often start showing here if they will. forum
  • Weeks 4–6: Modal cycle endpoint for bodybuilding-style native MGF charts; gradual size/fullness claims that stick are more often reported toward the end of this window, not overnight. forum
  • Beyond ~6–8 weeks: Logging thins; pulsed training-day blocks remain more common than open-ended daily use. Continuous multi-month native MGF has sparse public documentation. forum
  • No useful change by ~3–4 weeks: Community advice is recheck training stimulus, calories, sleep, product identity, and half-life-driven timing — not automatic jump past mid-hundreds mcg. forum
  • After stopping: Training quality may hold briefly or feel unchanged; residual claims are anecdotal. Time off is commonly planned before re-run. anecdote

Around the dose 2

  • Clock: Training day, around the session — local IM/near-muscle culture, not a nightly GH pin. forum
  • After: Train the muscle you’re targeting in that log. MGF on a rest-forever plan is not the culture. forum

Cycles people discuss 10

  • Most common bodybuilding length: ~4–6 weeks of training-aligned use. forum
  • Shorter test / mesocycle: ~2–4 weeks to gauge recovery feel or match one training block before buying more vials. forum
  • Pulsed pattern: Heavy / progressive-overload days only — not continuous open-ended calendar dosing for most logs. forum
  • 10-day alternating “burst” with IGF-1 LR3 (modern clinic/blog protocol): ~10 days total, alternate peptides every other day (e.g., Day 1 MGF, Day 2 LR3 … → 5 doses each), then break — marketed as mimicking repair-then-growth timing; not a controlled trial standard. forum
  • Time off — common: ~2–4 weeks after a multi-week run appears in vendor-style language; some match off-time to on-time. forum
  • Time off — inconsistent: Others simply stop when the camp/mesocycle ends without formal washout math. forum
  • When to run: High-volume or progressive-overload phases and injury-adjacent rehab blocks more often than deep cuts. forum
  • Re-runs: Later bulks common; no solid long-term safety database for repeated gray-market native MGF cycles. forum
  • Stack-length note: When paired with IGF-1 LR3, LR3 windows are often shorter (e.g., ~10-day bursts or ~3–4 week lore) while MGF may span a 4–6 week recovery block — schedules vary by camp. forum
  • Exit / reassess flags discussed: Persistent site reactions, unresolved headache/fatigue, blood-sugar weirdness (especially with IGF partners), or zero training/recovery signal by mid-block. forum

Timing 13

  • Community half-life estimate: Non-PEG MGF is often summarized as ~5–7 minutes, but the reviewed sources did not establish this as a human parent-plasma half-life for the exact synthetic 24-amino-acid product. forum
  • Half-life (wider forum range): ~2–15 minutes class claims appear across boards and research-summary pages — order-of-magnitude “very short,” not a single published human PK parameter for every analog. forum
  • Alternate community estimate: Some summaries give ~2–5 minutes for synthetic MGF-Ct24E and attribute it to rapid proteolysis; no exact-product human parent-plasma measurement was established in the reviewed sources. forum
  • Why local IM post-workout: Minute-scale clearance is the core reason community practice injects near trained muscle soon after lifting rather than using once-daily systemic depot logic. forum
  • Vs PEG-MGF: PEGylation extends exposure (community claims span “several hours” to multi-day / ~48–72 h / ~5-day marketing figures depending on source) — native = acute local pulse; PEG = fewer pins, more systemic talk. forum
  • After clear: Users separate “peptide already gone” from multi-day training adaptations hoped for (satellite-cell cascade storytelling). anecdote
  • Injection timing default: Immediately or within ~30–60 minutes post-resistance training into trained sites. forum
  • With IGF-1 LR3 timing lore: MGF (or PEG-MGF) soon post-workout for early “proliferation / satellite-cell” coverage; LR3 hours later (~4–8 h), next day, or on alternate days for “differentiation / protein synthesis” — complementary two-wave story, not a proven sequence RCT. forum
  • Alternate-day MGF vs LR3: Older boards and modern 10-day alternating blogs separate proliferative and growth days rather than stacking both every session. forum
  • Vs IGF-1 DES: Both short/local and workout-tied; DES is truncated IGF-1 with strong free-IGF lore; MGF is E-peptide / splice-variant lore — different molecules despite similar pin habits. forum
  • Endogenous timing backdrop: Natural MGF expression is discussed as rising after mechanical load (exercise physiology summaries sometimes cite multi-hour to ~72 h recovery windows for local IGF/MGF expression) — that endogenous timeline is not the same as exogenous peptide plasma half-life. forum
  • Glucose timing: Native MGF alone is usually framed as milder insulin-like risk than LR3/insulin, but stack partners and high mcg still prompt carb awareness talk. forum
  • Stabilized analogs: Research and black-market products sometimes use D-amino acids in the central “QRRK” region (and related tricks) to slow proteolysis — half-life claims then may not match pure native L-peptide lore. trial

More on what it is 10

  • Why people use it: Local post-workout “repair pulse” meant to expand satellite-cell / myoblast pool after mechanical damage, then let training, food, and later IGF signals “fill” those cells — contrasted with longer PEG-MGF and systemic IGF-1 LR3. forum
  • Two-signal model (Goldspink-class lore): Early MGF-E framed as proliferative / satellite-cell activating; later mature IGF-1 / IGF-1Ea-class signaling framed as differentiation and protein synthesis. This sequential story drives MGF→LR3 stack culture. forum
  • Mechanism talk: Load/damage upregulates local IGF-1Ec expression; MGF-E is discussed as acting partly independent of classic IGF-1 receptor storytelling in some write-ups (receptor identity still debated in literature summaries). forum
  • Identity caveat: Vials labeled “MGF” may be native L-peptide, D-amino-acid–stabilized analogs, C-terminal amidated black-market variants, wrong species sequence, or PEG product mis-sold as native — COA/identity testing ideal, not guaranteed. forum
  • Research lens: Match half-life claims, mcg charts, and outcome stories to construct (MGF-E vs full-length vs PEG vs stabilized) and to training stimulus; endogenous expression ≠ exogenous vial pharmacokinetics. forum
  • What it is: Mechano Growth Factor is a community label spanning the load-associated IGF-1Ec splice transcript/prohormone story and synthetic short E-domain peptides. A review found no analogous endogenous 24-amino-acid peptide product identified in cells, tissues or fluids; gray-market vial identity is therefore not interchangeable with endogenous IGF-1Ec. Not an FDA-approved physique drug. trial
  • Sequence lore: Human native E-peptide sequence often given as YQPPSTNKNTKSQRRKGSTFEERK (~2.9 kDa class). Rodent naming (IGF-1Eb vs human Ec) confuses product labels and papers. trial
  • Evidence posture: Denser cell/animal expression and satellite-cell work than large human RCTs of gray-market injectable MGF for physique goals. Observational human biopsy work measures endogenous MGF mRNA after exercise — not proof that research-chem vials work the same way. animal
  • What it is not: Not HGH, not insulin, not IGF-1 LR3, not IGF-1 DES, not PEG-MGF (unless mislabeled), not a SARM, not an approved hypertrophy or injury therapy. trial
  • Replication honesty: Independent lab work (Fornaro et al. 2014 class finding, widely cited in critical reviews) reported no clear proliferative effect of synthetic MGF E-peptide on myoblasts or primary muscle stem cells under their conditions — a real conflict with classic Goldspink-lab framing that forums often omit. lab

Stacks 13

  • + IGF-1 LR3 (top dual stack): “Two-wave / sequential” lore — MGF local early for satellite-cell proliferation talk; LR3 later or alternate days for longer IGF-driven growth/protein-synthesis talk. Sample sketches vary (e.g., MGF ~100–300 mcg PWO days; LR3 on its own chart bands, often tens of mcg). Glucose vigilance rises with LR3. forum
  • 10-day alternating MGF / LR3 protocol (public blog/clinic style): Alternate peptides every other day for 10 days (5 doses each), then ≥2–4 weeks off — short “burst,” not a universal standard. forum
  • Same-day staggered timing: PEG-MGF or MGF within ~30 minutes post-workout, IGF-1 LR3 ~4–8 hours later — another common complementary-story schedule. forum
  • + IGF-1 DES: Two short/local pulses near trained muscle (DES free-IGF lore + MGF E-peptide lore) — advanced, expensive, heavily confounded. forum
  • Vs / with PEG-MGF: Switch for convenience; sequential native “pulse” + PEG “coverage”; or call native+PEG redundant because both aim at MGF biology — practices and opinions conflict. forum
  • + HGH / somatropin: GH-axis growth/recovery stack — dual attribution; more total growth-pathway load. Some write-ups claim combining MGF with HGH improves outcomes vs either alone (anecdote/preclinical storytelling). forum
  • + CJC-1295 (often no DAC) + Ipamorelin: Secretagogue pulse support upstream while MGF covers post-training local repair lore; timing usually separated (GHS AM/bed fasted patterns vs MGF PWO). forum
  • + Sermorelin / Tesamorelin: Alternate GHRH-class partners in modern peptide stacks. forum
  • + MK-677: Oral GH-secretagogue + MGF — appetite/water from MK plus any nonspecifics; confounded recomp/recovery talk. forum
  • + BPC-157 (± TB-500 / “Wolverine” style): Soft-tissue healing peptides with muscle-specific MGF lore — popular injury-adjacent recovery stack; different pathways, credit split. forum
  • AAS bulks: MGF layered onto steroid cycles in advanced camps — multi-drug confounds dominate outcome claims. forum
  • Insulin caution: Additive hypoglycemia risk if combined with insulin or aggressive IGF-1 LR3 — advanced/high-risk territory in forum lore. forum
  • Training + surplus + protein: Progressive overload, calories, and sleep are repeatedly credited when logs look good — non-pharmacologic half of the stack. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • Injection-site reactions (most common): Pain, redness, warmth, itching, swelling, bruising, tenderness — often worse with poor IM technique or multi-site micro-injecting. forum
  • Persistent / spreading site reactions: Reactions lasting >48–72 hours, worsening, or looking infected are community stop-and-evaluate flags. forum
  • Systemic nonspecifics: Headache, fatigue, flu-like notes, mild nausea or dizziness in a minority of logs. forum
  • Hypoglycemia caution: Usually framed as lower risk for native MGF alone than for IGF-1 LR3 or insulin, but not zero — risk rises sharply in stacks with LR3, insulin, or aggressive carb restriction. Carb access and awareness are common stack advice. forum
  • Blood-sugar fluctuations: Minority reports; reassess dose/stack if glucose feels unstable. forum
  • GH / IGF feedback lore: Occasional forum claims that exogenous MGF can blunt perceived GH-secretagogue “feel” or reduce GH-related bloating/hunger via feedback storytelling — anecdote-level, not established PK. anecdote
  • Uneven / local hypertrophy talk: Theoretical preferential local growth with aggressive repeated site IM — lore-level, not measured incidence. forum
  • Allergy / hypersensitivity: Rare severe allergic reactions are emergency-care territory if swelling, breathing difficulty, or systemic rash appear. forum
  • IM technique risks: Nerve/vessel injury, deeper infection, abscess, and worse post-injection pain than SubQ if technique is poor. forum
  • Desensitization / open-ended use: Continuous multi-month use is less favored than pulsed blocks; desensitization talk is thinner for native MGF than for long IGF analogs but cycling culture still applies. forum
  • Pregnancy / nursing / major illness / minors: Community and cautious protocol language treat these as avoid-without-specialist-care zones. forum
  • Mitogenic / malignancy pathway caution: Growth-factor / IGF-axis signaling is proliferation- and anti-apoptosis–related; IGF-1Ec expression has been discussed in tumor-biology reviews. Active or recent cancer, unexplained lumps, or proliferative disease are hard avoid zones in cautious write-ups. trial
  • Replication / efficacy uncertainty as a risk: If the E-peptide mechanism does not translate (see negative independent cell work), users still accept injection and gray-market product risks for unclear benefit. lab
  • Cardiac research backdrop: Preclinical cardiac MGF work exists; human cardiac safety of exogenous gray-market MGF is not established — extra caution lore if significant heart disease. animal
  • Source quality: Contamination, underdosing, wrong peptide, native vs PEG mislabel, C-terminal amidated or other black-market analogs (Esposito et al. 2012 class analytical findings on illicit products) — structural gray-market risk independent of mechanism. trial
  • Anti-doping: Explicitly listed — WADA Prohibited List S2 growth factors include “Mechano growth factors (MGFs)” at all times; IGF-1 and analogues also prohibited. Tested athletes should assume detection risk. trial
  • Legal / regulatory: Research-chemical / “not for human consumption” labeling common; not FDA-approved for physique or injury use; jurisdiction varies. trial
  • Not risk-free: Missing a side effect in one log ≠ safety evidence; research-chemical framing does not erase sterility, growth-pathway, identity, or anti-doping risks. forum

Updated: 2026-08-21

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →